Jagsonpal Q2FY27 consolidated revenue up 29% to ₹964 Mn as Aequitas consolidates; reiterates ₹5,000 Mn Mission 2028
Q2FY27 consolidated revenue up 29% to ₹964 Mn; standalone H1 EBITDA up 11.3% and PAT up 10.3%; cash ₹1,347 Mn.
By ScoutQuest · · 1 min read
- Consolidated Q2FY27 Revenue
- ₹964 Mn, up 29%
- Standalone H1FY27 EBITDA
- ₹375 Mn (up 11.3%)
- Cash
- ₹1,347 Mn
- Period
- Q2 and H1 FY27 (quarter ended September 30, 2026)
- Positioning
- A 100% India-centric, asset-light branded-generics company since 1964 spanning Gynaecology, Orthopaedics, Dermatology, Wellness and Critical care, reaching 1,37,000+ doctors and 1,000+ hospitals.
📈 Consolidated Q2FY27 revenue was ₹964 Mn, up 29%, with Aequitas consolidated from Q2; standalone revenue rose 9.3% to ₹814 Mn with EBITDA of ₹185 Mn at a 22.7% margin and PAT flat at ₹126 Mn. For H1FY27 standalone revenue was ₹1,636 Mn (up 9.0%), EBITDA ₹375 Mn (up 11.3%) and PAT ₹258 Mn (up 10.3%).
📌 The company describes itself as an asset-light, India-centric branded-generics player; it says Aequitas opened the hospital channel with access to 1,000+ hospitals and that it completed the Group Pharma Wellness portfolio acquisition on 1st October 2026.
🎯 Management states it invested ahead of growth in Q2 (hospital team, Aequitas business head, wellness marketing) and expects benefits from Q3, with quarterly revenue to cross ₹1,000 Mn in Q3FY27. The presentation lists a Mission 2028 target of ₹5,000 Mn revenue against ₹2,872 Mn in FY26, and an Aequitas target of ~₹10 Cr EBITDA by 2028.
💰 The company points to its FY22-FY26 track record (revenue CAGR 7.2%, Op. EBITDA CAGR 24.9%), ₹1,347 Mn cash and a 200% dividend as backing, and says it remains confident of adding further accretive acquisitions.
Also from Jagsonpal Pharmaceuticals
Q2 FY27 call: management expects quarterly revenue to cross INR100 crore in Q3, keeps INR500 crore FY28 vision
3 Nov 2026
Audio recording of Jagsonpal Pharmaceuticals Q2 FY27 earnings conference call held October 29, 2026 posted on website
29 Oct 2026
Q2 & H1 FY27 Results Approved; Dividend Paid, ESOP Allotment, 85% Stake Acquired
28 Oct 2026
More numbers
- Consolidated revenue from operations, Q2FY27964 (₹ Mn)
- Consolidated revenue growth, Q2FY2729%
- Consolidated revenue from operations, H1FY271,786 (₹ Mn)
- Standalone revenue, Q2FY27814 (₹ Mn)
- Standalone revenue, H1FY271,636 (₹ Mn)
- Standalone EBITDA, H1FY27375 (₹ Mn)
- Standalone PAT, H1FY27258 (₹ Mn)
- Standalone EBITDA margin, Q2FY2722.7%
- Cash position, September 30, 2026₹1,347 Mn
- Aequitas all-cash consideration₹20.8 Cr
- Aequitas EBITDA target by 2028~₹10 Cr
- Revenue, FY262,872 (₹ Mn)
- Mission 2028 revenue target₹5,000 Mn
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.